Following its recent $43 million Series B funding, the company is expanding its data integration capabilities to include a broader range of devices, including wearables, heart failure monitoring, and remote patient monitoring.
Congratulations to Stanford Medicine on winning the 2023 Hearst Health Prize for its artificial intelligence solution that helps identify patients at risk for heart attack by scoring incidental coronary artery calcium (CAC) on non-gated chest CTs.
Late-Breaking Science sessions reveal revolutionary findings on severe aortic stenosis and mild-to-severe mitral regurgitation identification through innovative AI technology.
Researchers and engineers at Mayo Clinic and Ultromics developed technology that can detect HFpEF using a single A4C echocardiogram clip, to help clinicians detect a complex form of heart failure easily and accurately.
The Midwest company will begin offering EchoSolv, an artificial intelligence clinical decision support platform designed to help detect severe aortic stenosis, to providers throughout the country.
PulseAI, a leader in the development of cutting-edge AI-powered ECG software, has released the results of a clinical study that has shown the superiority of its deep learning AI over the Apple Watch ECG algorithm in the detection of atrial fibrillation.
NAPLES, Fla. – February 20, 2023 The NCH Healthcare System is proud to announce a $20 million naming gift from the Rooney Foundation, which is the philanthropic arm of the former U.S. Representative for Florida's 19th congressional district and his wife, Francis and Kathleen Rooney. In recognition of increasing their $8 million pledge announced last July, the entire cardiac program across NCH Healthcare System will be renamed “The Rooney Heart Institute.”
NAPLES, Fla. – February 21, 2023 On the heels of our historic $20 Million gift announcement made last week, NCH is proud to announce yet a second $20 million naming gift in as many weeks from Diana and Don Wingard. This generous gift will provide the necessary funds to ensure that the NCH Stroke program continues to provide the highest level of care and treatment to patients in Southwest Florida. Additionally, in recognition of the extraordinary pledge, the entire stroke program across NCH will be renamed the “Wingard Stroke Institute.”
When using this service, patients have the ability to upload and share data without limitations. From radiology CDs to PDFs or JPG files, patients can use their smartphone connected to the Patient Image Exchange app and upload images, share lab results, immunizations records, nurses’ notes, dental images and much more.
Ancora Heart has hired senior financial leader David J. Tucker as its chief financial officer. This is the company's second C-suite hire in 2022, following the addition of Mark Miles as chief commercial officer in June.
Geneticure, a global leader in the genetic variability of response to hypertension treatments, presented data at the 2022 American Heart Association Scientific Sessions meeting from a recent clinical study in which they were able to successfully predict patients who will respond to renal denervation (RDN). In addition, the Geneticure test for renal denervation also identified patients with an increase in blood pressure, following the procedure.
Long-awaited milestone gives physicians and their patients greater access to prescription cardiac arrhythmia detection solutions, including the company’s Cardea SOLO™ ECG System
MINNEAPOLIS, March 14, 2018 — Mardil Medical, Inc., today announced the first human implants of its VenTouch® Triad device. Designed as a combination therapy to simultaneously treat the dilated ventricle and the resulting distorted valve in patients suffering from Type IIIb Functional Mitral Valve Regurgitation (FMR), VenTouch is a less-invasive treatment for a condition that can, if left untreated, accelerate and worsen heart failure.
Washington, DC—The National Quality Forum (NQF) today issued a call to action to make shared decision making a standard of care for all patients, across settings and conditions. The new guide for healthcare providers, the National Quality Partners Playbook™: Shared Decision Making in Healthcare, offers vital guidance for this process of communication in which clinicians and patients work together to make healthcare decisions that align with what matters most to patients.
ORLANDO, Fla., March 10, 2018 — The Janssen Pharmaceutical Companies of Johnson & Johnson today announced late-breaking results of a new home-based clinical trial showing that a wearable continuous electrocardiogram (ECG) monitoring patch can identify people with asymptomatic atrial fibrillation (AFib) earlier and more efficiently than routine care.
At the American College of Cardiology’s 67th Annual Scientific Session and Expo, Siemens Healthineers has launched the next generation of syngo Dynamics, a cardiovascular imaging and information solution. The newest version of the software emphasizes enhanced security, widespread access, enterprise consistency, and structured reporting.
RIDGEFIELD, Conn. and INDIANAPOLIS, March 6, 2018 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today announced plans to expand their clinical trial program for Jardiance® in chronic heart failure with the EMPERIAL clinical trials.
REDWOOD CITY, Calif., March 1, 2018 — HeartFlow, Inc. today announced that it has entered into a licensing and technology transfer agreement with Cedars-Sinai in Los Angeles for AutoPlaque technology, a software tool used to detect and characterize coronary artery plaque based on coronary computed tomography angiography (CCTA) images.
MIAMI, Feb. 27, 2018 — Longeveron announced that its pioneering clinical trial to treat infants with Hypoplastic Left Heart Syndrome officially started with the first patient receiving the company's mesenchymal stem cell therapy in a procedure performed at the University of Maryland Medical Center in Baltimore.
DUBLIN — February 26, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that the U.S. Food and Drug Administration (FDA) has approved a new arm indication for the Guardian(TM) Sensor 3.
INDIANAPOLIS, Feb. 26, 2018 — Trulicity® (dulaglutide) significantly improves A1C (average blood sugar concentration over two to three months) when added to ongoing treatment with a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, according to results from AWARD-10, a new Phase 3b clinical study. These data were published online first in The Lancet Diabetes & Endocrinology.
DUBLIN — February 20, 2018 — Medtronic plc (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2018, which ended January 26, 2018.
SANTA CLARA, Calif.—February 20, 2018—Cardiva Medical®, an innovator in the field of vascular closure, today announced that the company has closed on $11 million in additional financing — bringing total equity and debt financing in the current round to $41 million.
DUBLIN and VIENNA — February 15, 2018 — Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that new data from its at-home pediatric study of the MiniMed(TM) 670G system in patients 7-13 years of age were presented at the Advanced Technologies & Treatments for Diabetes (ATTD) 11th International Conference in Vienna, Austria.
PETAH TIKVA, Israel, February 15, 2018 — DreaMed Diabetes, developer of diabetes management solutions, announced today that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.
REDWOOD CITY, Calif.—HeartFlow, Inc. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial expansion of the HeartFlow® FFRct Analysis, continued technology innovation and additional clinical studies.
DANVERS, Mass., Feb. 13, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support and recovery technologies, announced today the launch of a new indication and Women's Initiative focused on heart recovery education and awareness.
Tokyo-based Terumo Corporation has today announced an investment of £33 million in one of its subsidiary companies, Vascutek Limited, located near Glasgow.
Hundreds of hospitals across the United States will have access to tools and resources to help improve care and lower readmission rates for myocardial infarction (MI) patients as part of the American College of Cardiology’s expanded Patient Navigator Program: Focus MI Quality Campaign.
COPENHAGEN, February 8, 2018 — Acesion Pharma ("Acesion" or the Company), a Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, announces today it has received approval to commence its first clinical study for its lead compound AP30663. The phase 1 study in healthy subjects will be conducted at the Centre for Human Drug Research (CHDR) in the Netherlands and is due to start in March 2018.
Pittsburgh, PA, February 7, 2018 — DoctorsReport.com, the new Website and mobile app that give you instant access to data doctors report from almost one million doctors’ offices across the nation, has released its current list of the nation’s 14 Influenza hot spots (by metro area) in the country.
KFAR MALAL, Israel, Feb. 5, 2018 — Medial EarlySign, a leader of machine-learning based solutions to improve non-communicable disease management, today announced the results of an additional clinical data study in the domain of diabetes — identifying diabetic patients who are at highest risk for having renal dysfunction within one year.
DUBLIN and LEIPZIG — January 30, 2018 — Medtronic plc (NYSE: MDT) today added to its robust body of clinical evidence supporting the IN.PACT(TM) Admiral(TM) drug-coated balloon (DCB) with new presentations that demonstrated durable and consistent clinical outcomes in peripheral artery disease (PAD).
